253 related articles for article (PubMed ID: 18794281)
1. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.
Cornelius CA; Quenee LE; Overheim KA; Koster F; Brasel TL; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2008 Dec; 76(12):5588-97. PubMed ID: 18794281
[TBL] [Abstract][Full Text] [Related]
2. Complete Protection Against
Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
Front Immunol; 2022; 13():793382. PubMed ID: 35154110
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
4. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.
Quenee LE; Ciletti NA; Elli D; Hermanas TM; Schneewind O
Vaccine; 2011 Sep; 29(38):6572-83. PubMed ID: 21763383
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
[TBL] [Abstract][Full Text] [Related]
7. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
9. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
[TBL] [Abstract][Full Text] [Related]
10. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
11. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
Quenee LE; Schneewind O
Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
[TBL] [Abstract][Full Text] [Related]
12. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V
Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825
[TBL] [Abstract][Full Text] [Related]
13. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
14. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
[TBL] [Abstract][Full Text] [Related]
15. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.
Branger CG; Sun W; Torres-Escobar A; Perry R; Roland KL; Fetherston J; Curtiss R
Vaccine; 2010 Dec; 29(2):274-82. PubMed ID: 20979987
[TBL] [Abstract][Full Text] [Related]
17. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).
Fellows P; Adamovicz J; Hartings J; Sherwood R; Mega W; Brasel T; Barr E; Holland L; Lin W; Rom A; Blackwelder W; Price J; Morris S; Snow D; Hart MK
Vaccine; 2010 Nov; 28(49):7748-56. PubMed ID: 20920572
[TBL] [Abstract][Full Text] [Related]
18. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.
Qi Z; Zhou L; Zhang Q; Ren L; Dai R; Wu B; Wang T; Zhu Z; Yang Y; Cui B; Wang Z; Wang H; Qiu Y; Guo Z; Yang R; Wang X
Vaccine; 2010 Feb; 28(6):1655-60. PubMed ID: 20079562
[TBL] [Abstract][Full Text] [Related]
19. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
[TBL] [Abstract][Full Text] [Related]
20. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
